<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415606</url>
  </required_header>
  <id_info>
    <org_study_id>ZM-QCC-01</org_study_id>
    <nct_id>NCT04415606</nct_id>
  </id_info>
  <brief_title>QuikClot Control+ Hemostatic Dressing Use in Mild to Moderate Bleeding</brief_title>
  <official_title>A Pre-Market, Prospective, Controlled, Multicenter, Single Blinded, Pivotal Clinical Investigation of QuikClot Control+ for Use in Mild to Moderate Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Z-Medica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Z-Medica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      QuikClot Control+ Hemostatic Dressing (QuikClot+) is indicated for temporary control of&#xD;
      internal organ space bleeding for patients displaying Class III or Class IV Bleeding. It may&#xD;
      also be used for control of severely bleeding wounds such as surgical wounds and traumatic&#xD;
      injuries. QuikClot Control+ is also indicated for temporary control of mild to moderate&#xD;
      bleeding in cardiac surgical procedures. QuikClot Control+ is also indicated for use to&#xD;
      control bleeding from bone surface following sternotomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subject will not know which arm they were randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of hemostasis</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>The primary effectiveness endpoint is the rate at which subjects achieve hemostasis (grade 0 bleed) through up to 10 minutes of application and compression of the bleeding site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of hemostasis</measure>
    <time_frame>Up to 5 minute and 10 minutes</time_frame>
    <description>Proportion of subjects achieving hemostasis (grade 0 bleed) measured at 5 minute and 10 minutes of application and compression at the bleeding site.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>QuikClot Control+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuikClot Control+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard gauze</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard gauze per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QuikClot Control+</intervention_name>
    <description>Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.</description>
    <arm_group_label>QuikClot Control+</arm_group_label>
    <arm_group_label>Standard gauze</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range greater than or equal to 18 years old&#xD;
&#xD;
          -  Willing and able to give prior written informed consent&#xD;
&#xD;
          -  Requiring cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject undergoing emergency surgery for any reason&#xD;
&#xD;
          -  Subject has active or potential infection at the surgical site or endocarditis&#xD;
&#xD;
          -  eGFR less that lo mL per minute&#xD;
&#xD;
          -  Subject who is currently participating in an investigational drug or another device&#xD;
             trial (excluding registries)&#xD;
&#xD;
          -  Leucopenia (WBC &lt; 3.5x 103/µL), or acute anemia (Hgb &lt; 10.0 mg/dL or 6 mmol/L), or&#xD;
             thrombocytopenia (platelet count &lt; 50x 103/µL), or history of bleeding diathesis or&#xD;
             coagulopathy, or HIT positive&#xD;
&#xD;
          -  Other medical, social, or psychological conditions that, in the opinion of the&#xD;
             Investigator, precludes the subject from appropriate consent or adherence to the&#xD;
             protocol required follow-up exams&#xD;
&#xD;
          -  Active illicit drug use, verbally confirmed with the patient&#xD;
&#xD;
          -  Severe Liver dysfunction confirmed via Child-Pugh of B-C or MELD &gt; 10&#xD;
&#xD;
          -  Female who is pregnant at screening. Confirmation by urine or serum pregnancy test&#xD;
&#xD;
          -  Incarcerated or unable to give voluntary informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mumashir Mumtaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Pinnacle</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajesh Raju</last_name>
    <phone>475-434-0900</phone>
    <email>araju@z-medica.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Health</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Reece, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Keeling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portneuf Medical Center / Snake River Research PLCC</name>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <zip>83201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob DeLaRosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Moon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bryan Heart</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mubashir Mumtaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Sultan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

